The FDA approved Rasonque (daraxonrasib) on August 26, 2026 — the first RAS inhibitor in pancreatic cancer. Within 48 hours, the launch conversation on X reached 700,000+ impressions across our curated network. This is who drove it, what they said, and how the amplification actually flowed.
Pancreatic cancer physicians treated August 26 as a generational marker. Dr. Bekaii-Saab:
"Transformational !!! Decades of hard work — I remember a closing slide on all my pancreas talks over the last 2+ decades about the light at the end of the tunnel - well here we are moving into the light ! Just love it and more to come !!"
Dr. Maitra called it the "culmination of years of research & clinical trials," and Dr. Park took the story to CNN with Wolf Blitzer — a rare mainstream moment for a GI oncologist.
The most-retweeted physician posts were explainers: label figures, mechanism graphics, and who-qualifies breakdowns. Dr. Ergün alone drew 11 distinct amplifier edges in the graph — the strongest physician amplification signature of the launch window.
Dr. Maitra flagged it within hours of the approval:
"The @FDA Daraxonrasib (Rasonque) approval is REALLY broad & the 'OR' in the indication below potentially opens the door for a 'soft 1st line' extension. Also, no requirement to document KRAS status..."
Dr. Gong put the first-line question directly to colleagues: fit for multi-agent chemo — daraxonrasib first, or chemo? "Imagine co-pay and drug will be costly w/payor pushback."
Revolution Medicines set the list price at $39,800 per 30-day supply — about $478,000 a year. By day two the access debate was running alongside the celebration. Dr. Rajkumar:
"We live in an infinite resources scenario mindset despite finite resources. This type of pricing which is all too common for new cancer drugs is not sustainable."
Dr. Kurzrock, who celebrated the science, also posted the launch window's sharpest tempering line:
"Daraxonrasib moves undruggable to druggable. But come on. 50 percent dead at just over a year is not exactly wonderful"
Dr. Olivier's thread examined the efficacy-effectiveness gap and where the label extends past the trial population ("not candidates for multiagent systemic therapy") — the evidence, he argued, ends before the label does.
The network's gravity centers were not individual physicians but the sponsor, the regulator, and advocacy: @RevMedicines (27 mention edges), @FDA (26), @OncoAlert (19), @KRASKickers (13), and @PanCAN (11). Mainstream media carried the biggest single audiences — ABC News (48K impressions), Bloomberg (38K), Forbes (28K) — while Memorial Sloan Kettering and Mayo Clinic gave the approval institutional weight.
Every node is an account in the launch conversation; node size = impressions, gold ring = verified US physician. Solid orange edges are mentions, dashed blue are retweets. Filter by US physicians, media, or the OncoAlert network — and click any node to open the account on X.
Full RASolute 302 KOL reaction → Watch: the 2-minute KOL video →